# *Figure 1*




= SOLID SUPPORT

**R** = TERMINAL PROTECTING GROUP
FOR EXAMPLE:
DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR INVERTED DEOXYABASIC SUCCINATE)

(2) = CLEAVABLE LINKER
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR INVERTED DEOXYABASIC SUCCINATE)




INVERTED DEOXYABASIC SUCCINATE LINKAGE




GLYCERYL SUCCINATE LINKAGE

***Figure 2***


6646.96
6850.04
100
90
80
70
60
50
40
30
20
10
0
% Intensity
650
4520
8390
Mass (m/z )

*Figure 3*


dsRNA OR 3' 3'
DICER
siRNA duplex
expressed/synthetic siRNA
Active siRNA complex
Target Recognition
RISC complex
RNA synthesis by RdRP
Additional siRNA generated by DICER (Plasterk, 2002, Science, 296, 1263-1265)
Endonuclease Cleavage of Target

# *Figure 4*

**A**

SENSE STRAND (SEQ ID NO 2438)
ALL POSITIONS RIBONUCLEOTIDE EXCEPT POSITIONS (N N)

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-($N_S$N) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2439)
ALL POSITIONS RIBONUCLEOTIDE EXCEPT POSITIONS (N N)

**B**

SENSE STRAND (SEQ ID NO 2440)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-OM EXCEPT POSITIONS (N N)

5'- N N N N N N N N N N N N N N N N N N N ($N_S$N) -3'
3'- L-($N_S$N) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2441)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N)

**C**

SENSE STRAND (SEQ ID NO 2442)
ALL PYRIMIDINES = 2'-O-ME OR 2'-FLUORO EXCEPT POSITIONS (N N)

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-($N_S$N) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2443)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N)

**D**

SENSE STRAND (SEQ ID NO 2444)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-($N_S$N) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2441)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N)

**E**

SENSE STRAND (SEQ ID NO 2445)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N)

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-($N_S$N) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2441)
ALL PYRIMIDINES = 2'-FLUORO AND ALL PURINES = 2'-O-ME EXCEPT POSITIONS (N N)

**F**

SENSE STRAND (SEQ ID NO 2444)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

5'- B-N N N N N N N N N N N N N N N N N N N (N N)-B -3'
3'- L-($N_S$N) N N N N N N N N N N N N N N N N N N N -5'

ANTISENSE STRAND (SEQ ID NO 2446)
ALL PYRIMIDINES = 2'-FLUORO EXCEPT POSITIONS (N N) AND ALL PURINES = 2'-DEOXY

POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT
L = GLYCERYL MOIETY THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

# *Figure 5*

**A**

SENSE STRAND (SEQ ID NO 2447)

5'- iB- A U C A G U C A G U A U C U G C A G A *T T*-iB -3'

3'- L-$T_S$*T* U A G U C A G U C A U A G A C G U C U -5'

ANTISENSE STRAND (SEQ ID NO 2448)

**B**

SENSE STRAND (SEQ ID NO 2449)

5'- a *u c* a g *u c* a g *u* a *u c u* g *c* a g a $T_S$*T* -3'

3'- L-$T_S$*T u* a g *u c* a g *u c* a *u* a g a *c g u c u* -5'

ANTISENSE STRAND (SEQ ID NO 2450)

**C**

SENSE STRAND (SEQ ID NO 2451)

5'- iB-A u c A G u c A G u A u c u G c A G A *T T*-iB -3'

3'- L-$T_S$*T u* A G *u c* A G *u c* A *u* A G A *c* G *u c u* -5'

ANTISENSE STRAND (SEQ ID NO 2452)

**D**

SENSE STRAND (SEQ ID NO 2453)

5'- iB-*A u c A G u c A G u A u c u G c A G A T T*-iB -3'

3'- L-$T_S$*T u* a g *u c* a g *u c* a *u* a g a *c g u c u* -5'

ANTISENSE STRAND (SEQ ID NO 2450)

**E**

SENSE STRAND (SEQ ID NO 2454)

5'- iB-A *u c* A G *u c* A G *u* A *u c u* G *c* A G A *T T*-iB -3'

3'- L-$T_S$*T u* a g *u c* a g *u c* a *u* a g a *c g u c u* -5'

ANTISENSE STRAND (SEQ ID NO 2450)

**F**

SENSE STRAND (SEQ ID NO 2453)

5'- iB-*A u c A G u c A G u A u c u G c A G A T T*-iB -3'

3'- L-$T_S$*T u A G u c A G u c A u A G A c G u c u* -5'

ANTISENSE STRAND (SEQ ID NO 2455)

lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro
*italic lower case = 2'-deoxy-2'-fluoro*
underline = 2'-O-methyl

*ITALIC UPPER CASE = DEOXY*
B = INVERTED DEOXYABASIC
L = GLYCERYL MOIETY OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

*Figure 6*



*Figure 7*


A
5'- R1 NNNNNNNNNNNNNNNNNNN X X
NNN X X
3'-EXTENSION
B
5'- R1 NNNNNNNNNNNNNNNNNNN X X
3'- R2 NNNNNNNNNNNNNNNNNNN X X
MELT AND CLONE
C
5'- R1 — NNNNNNNNNNNNNNNNNNNNNXXXXNNNNNNNNNNNNNNNNNNN — R2 -3'
3'- PRIMER -5'
U6 snRNA PROMOTER
TERMINATION REGION
R1 = RESTRICTION SITE #1
R2 = RESTRICTION SITE #2
N = A, G, C, or T
X = A, G, C, or T LOOP SEQUENCE

*Figure 8*


A
5'-
R1
NNNNNNNNNNNNNNNNNNN
R2
X X X X X X
3'-EXTENSION
B
5'-
R1
NNNNNNNNNNNNNNNNNNN
R2
X X X X X X
3'-
R1
NNNNNNNNNNNNNNNNNNN
R2
X X X X X X
CLEAVAGE WITH RESTRICTION ENZYMES 1 AND 2
C
5'-
NNNNNNNNNNNNNNNNNNN
3'-
NNNNNNNNNNNNNNNNNNN
CLONE
U6 snRNA PROMOTER
U6 snRNA PROMOTER
R1 = RESTRICTION SITE #1
R2 = RESTRCTION SITE #2
N = A, G, C, or T
X = A, G, C, or T

Figure 9: Target site Selection using siRNA



*Figure 10*




R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

# Figure 11: Modification Strategy



# Figure 12: Inhibition of VEGF-Induced Angiogenesis by siRNAs



**Figure 13: Site 3854 and 3948 KDR RNAi, 4/5, 7/8 and 9/10 chemistry in HAEC cells**



# Figure 14: Phosphorylated siNA constructs



Phosphates can be modified as described herein

Asymmetric hairpin siNA






Asymmetric duplex siNA


(n) = number of base pairs (e.g. 3-18 bp)

# Figure 15: 5'-phosphate modifications